Spyre Therapeutics Return On Equity vs. Revenue

SYRE Stock   27.99  0.72  2.64%   
Based on Spyre Therapeutics' profitability indicators, Spyre Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Spyre Therapeutics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(1.84)
Current Value
(1.93)
Quarterly Volatility
0.59439626
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Spyre Therapeutics' Days Sales Outstanding is projected to decrease significantly based on the last few years of reporting. The current year's EV To Sales is expected to grow to 52.25, whereas Operating Cash Flow Sales Ratio is projected to grow to (107.13). At present, Spyre Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 6.5 M, whereas Income Before Tax is projected to grow to (321.9 M).
For Spyre Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spyre Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spyre Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spyre Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spyre Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(37.90)
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Spyre Therapeutics Revenue vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Spyre Therapeutics's current stock value. Our valuation model uses many indicators to compare Spyre Therapeutics value to that of its competitors to determine the firm's financial worth.
Spyre Therapeutics is currently regarded as top stock in return on equity category among its peers. It also is currently regarded number one company in revenue category among its peers . At present, Spyre Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Spyre Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Spyre Revenue vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Spyre Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.92
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Spyre Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
886 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Spyre Revenue vs Competition

Spyre Therapeutics is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 1.18 Trillion. Spyre Therapeutics adds roughly 886,000 in revenue claiming only tiny portion of equities under Health Care industry.

Spyre Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Spyre Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spyre Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Spyre Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Spyre Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income302 K317.1 K
Operating Income-242.3 M-230.2 M
Income Before Tax-338.8 M-321.9 M
Total Other Income Expense Net-96.5 M-91.7 M
Net Loss-338.8 M-321.9 M
Net Interest Income6.1 M6.5 M
Interest Income6.1 M6.5 M
Net Loss-338.8 M-321.9 M
Income Tax Expense-26 K-27.3 K
Net Loss(49.12)(51.58)
Income Quality 0.29  0.28 
Net Income Per E B T 1.00  1.10 

Spyre Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Spyre Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spyre Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spyre Therapeutics' important profitability drivers and their relationship over time.

Use Spyre Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spyre Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Spyre Therapeutics Pair Trading

Spyre Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Spyre Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spyre Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spyre Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spyre Therapeutics to buy it.
The correlation of Spyre Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spyre Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spyre Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spyre Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Spyre Therapeutics position

In addition to having Spyre Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Books Thematic Idea Now

Books
Books Theme
Companies involved in publishing of books, newspapers, periodicals and other mass publications. The Books theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Books Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:
Check out World Market Map.
For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
To fully project Spyre Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spyre Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spyre Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Spyre Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Spyre Therapeutics investors may work on each financial statement separately, they are all related. The changes in Spyre Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Spyre Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.